DK1144006T3 - Synergistisk inhibering af HIV-1-fusion og -binding, præparater og antistoffer dertil - Google Patents

Synergistisk inhibering af HIV-1-fusion og -binding, præparater og antistoffer dertil

Info

Publication number
DK1144006T3
DK1144006T3 DK99966466T DK99966466T DK1144006T3 DK 1144006 T3 DK1144006 T3 DK 1144006T3 DK 99966466 T DK99966466 T DK 99966466T DK 99966466 T DK99966466 T DK 99966466T DK 1144006 T3 DK1144006 T3 DK 1144006T3
Authority
DK
Denmark
Prior art keywords
hiv
antibodies
preparations
fusion
binding
Prior art date
Application number
DK99966466T
Other languages
Danish (da)
English (en)
Inventor
William C Olson
Paul J Maddon
Original Assignee
Progenics Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc filed Critical Progenics Pharm Inc
Application granted granted Critical
Publication of DK1144006T3 publication Critical patent/DK1144006T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK99966466T 1998-12-16 1999-12-16 Synergistisk inhibering af HIV-1-fusion og -binding, præparater og antistoffer dertil DK1144006T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21279398A 1998-12-16 1998-12-16
US11253298P 1998-12-16 1998-12-16
PCT/US1999/030345 WO2000035409A2 (fr) 1998-12-16 1999-12-16 Inhibition synergique de la fusion et la liaison du vih-1 et composition et anticorps s'y rapportant

Publications (1)

Publication Number Publication Date
DK1144006T3 true DK1144006T3 (da) 2007-11-26

Family

ID=26810060

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99966466T DK1144006T3 (da) 1998-12-16 1999-12-16 Synergistisk inhibering af HIV-1-fusion og -binding, præparater og antistoffer dertil

Country Status (13)

Country Link
EP (2) EP2088158A3 (fr)
JP (1) JP2002538771A (fr)
AT (1) ATE375802T1 (fr)
AU (3) AU773175B2 (fr)
CA (1) CA2355607A1 (fr)
CY (1) CY1107858T1 (fr)
DE (1) DE69937369T2 (fr)
DK (1) DK1144006T3 (fr)
ES (1) ES2296416T3 (fr)
HK (1) HK1041207B (fr)
MX (1) MXPA01006097A (fr)
PT (1) PT1144006E (fr)
WO (1) WO2000035409A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0847452B1 (fr) 1995-06-07 2009-04-01 Progenics Pharmaceuticals, Inc. Anticorps monoclonal destiné à inhiber la fusion membranaire médiée par la glycoprotéine d'enveloppe de vih-1
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
WO2001043779A2 (fr) * 1999-12-16 2001-06-21 Tanox, Inc. Conjugues anti-hiv1 pour le traitement du vih
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US20020146415A1 (en) * 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
CA2471136A1 (fr) * 2001-12-21 2003-07-03 Micromet Ag Genes hybrides simples et doubles de chemokine/cytokine
PT1478738E (pt) * 2002-02-22 2009-02-16 Progenics Pharm Inc Anticorpo anti-ccr5
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
EP1981911A2 (fr) * 2006-01-30 2008-10-22 F.Hoffmann-La Roche Ag Compositions synergiques destinees au traitement du vih
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
BRPI0715794A2 (pt) 2006-08-17 2013-07-23 Hoffmann La Roche conjugado de anticorpo contra ccr5 e peptÍdeo antifusogÊnico
WO2008037419A1 (fr) 2006-09-29 2008-04-03 F. Hoffmann-La Roche Ag Anticorps dirigés contre le ccr5 et ses utilisations
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
EP2741777B1 (fr) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Procédés et compositions pharmaceutiques pour le traitement de l'hypertension pulmonaire
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3375697A (en) * 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
WO1997047319A1 (fr) * 1996-06-14 1997-12-18 Progenics Pharmaceuticals, Inc. Utilisations d'un recepteur de la chemokine dans l'inhibition de l'infection par le vih-1
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same

Also Published As

Publication number Publication date
EP2088158A2 (fr) 2009-08-12
AU2004205164A1 (en) 2004-09-16
ES2296416T3 (es) 2008-04-16
CA2355607A1 (fr) 2000-06-22
HK1041207A1 (en) 2002-07-05
EP1144006B1 (fr) 2007-10-17
CY1107858T1 (el) 2013-06-19
PT1144006E (pt) 2007-12-11
DE69937369D1 (de) 2007-11-29
HK1041207B (zh) 2007-12-28
MXPA01006097A (es) 2002-04-15
EP1144006A2 (fr) 2001-10-17
ATE375802T1 (de) 2007-11-15
AU2199600A (en) 2000-07-03
AU2004205165A1 (en) 2004-09-16
EP1144006A4 (fr) 2004-11-24
AU773175B2 (en) 2004-05-20
EP2088158A3 (fr) 2010-01-20
DE69937369T2 (de) 2008-07-24
JP2002538771A (ja) 2002-11-19
WO2000035409A3 (fr) 2000-09-14
WO2000035409A2 (fr) 2000-06-22

Similar Documents

Publication Publication Date Title
CY1107858T1 (el) Ccr5 αντισωματα pa14
DE69429095T2 (de) Humanisierte antikoerper
KR960704938A (ko) Fas 길항제 및 그의 용도(Fas Antagonists and Uses Thereof)
NO942912L (no) Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
ATE324381T1 (de) Mutiertes scfv-fragment des okt-3 antikörpers
KR960704576A (ko) CD40에 대한 항체(Antibodies to CD40)
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
HK1115607A1 (en) Human cytokine receptor
WO2003078468A3 (fr) Utilisation d'une substance active se liant a cd28 pour la preparation d'une composition pharmaceutique
CA2221893A1 (fr) Anticorps specifique de staphylococcus aureus et utilisations
ES2114547T3 (es) Anticuerpos monoclonales contra el virus de la hepatitis c.
MX9702422A (es) Anticuerpos recombinantes contra fas y adn para los mismos.
BR0007827A (pt) Anticorpos e fragmento fv que reconhecemantìgeno ior c2
CA2137551A1 (fr) Nouvelle molecule de cellule endotheliale qui facilite la fixation lymphocytaire chez l'homme
EP0349258A3 (fr) Procédé pour déterminer la différentiation d'une cellule-T humaine
DK557187A (da) Murin hybridoma lym-1, dermed fremstillet monoklonalt antistof og fremgangsmaade til fremstilling af antistoffet
DK557287A (da) Murin hybridoma lym-2, dermed fremstillet monoklonalt antistof og fremangsmaade til fremstilling af antistoffet
EP1734054A3 (fr) Anticorps monoclonaux contre la synthase de thymidylate humaine et hybridomes produisant ces anticorps